CN101785840A - Medicine combination for traumatic injury and rheumatoid arthritis treatment - Google Patents

Medicine combination for traumatic injury and rheumatoid arthritis treatment Download PDF

Info

Publication number
CN101785840A
CN101785840A CN200910077538A CN200910077538A CN101785840A CN 101785840 A CN101785840 A CN 101785840A CN 200910077538 A CN200910077538 A CN 200910077538A CN 200910077538 A CN200910077538 A CN 200910077538A CN 101785840 A CN101785840 A CN 101785840A
Authority
CN
China
Prior art keywords
weight portion
weight portions
vinegar
pharmaceutical composition
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910077538A
Other languages
Chinese (zh)
Inventor
陈纪鹏
洪绯
罗志毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Original Assignee
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhangzhou Pientzehuang Pharmaceutical Co Ltd filed Critical Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority to CN200910077538A priority Critical patent/CN101785840A/en
Publication of CN101785840A publication Critical patent/CN101785840A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a medicine combination for traumatic injury and rheumatoid arthritis treatment, which includes the raw materials of: veronica peregrine, angelica, cortex acanthopanacis, radix angelicae pubescentis, notopterygium root, rhizoma sparganii (prepared by vinegar), curcuma zedoary (prepared by vinegar), ground beeltle, folium artemisiae argyi, rhizoma corydalis (prepared by vinegar), pepper, dragon's blood, frankincense, lycopodium clavatum, activation herb, hematoxylon, menthol crystal, camphor and borneol. The medicine combination has the efficacies of invigorating the blood circulation, detumescence, relieving pain, relieving rheumatic pains and dissipating cold, and has remarkable curative effect on the treatment of traumatic injury, stasis swelling, waist and limb numbness and rheumatism.

Description

A kind of pharmaceutical composition for the treatment of traumatic injury, rheumatic ostalgia
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly a kind of pharmaceutical composition for the treatment of traumatic injury, rheumatic ostalgia.
Background technology
Traumatic injury mainly comprises owing to fall and pounce on, knife injury, hit, dodge pressure, scratch and athletic injury etc. and cause wound phenomenons such as pain, swelling, the muscle and tendon injury of part or whole body, damages of leaping up, hemorrhage, cyanosis of the skin, also comprises when breathing visceral injuries such as inside twinge.Traumatology side medicine China traumatology one art quite has speciality, and the wonderful swift merit of tool.Osteomiosis can connect, tendon breaking can continue, skin and flesh weak point, blood flow prolapse of rectum, not uncurable disease.Or with the maneuver of sensitivity, or, playing the effect of extremely bringing back to life in seconds with efficacious medicine.Rheumatism is that wind-cold damp pathogen is invaded due to the human body, and wind-cold damp pathogen causes muscle arteries and veins blocking barrier after invading human body, and " stagnation of QI and blood may bring about pain " often causes that thus congestion and swelling pain takes place at positions such as human synovial, periosteum, muscle, and pain unbearably.
Summary of the invention
One object of the present invention is to disclose a kind of pharmaceutical composition for the treatment of traumatic injury, rheumatic ostalgia; Another object of the present invention is to disclose this preparation of drug combination method.
The present invention seeks to be achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
Herba Veronicae Peregrinae 100-200 weight portion Radix Angelicae Sinensis 50-130 weight portion
Cortex Acanthopancis 120-240 weight portion Radix Angelicae Pubescentis 70-160 weight portion
Rhizoma Et Radix Notopterygii 70-160 weight portion vinegar system rhizoma sparganic 40-100 weight portion
Rhizoma Curcumae (processed with vinegar) 40-100 weight portion Eupolyphaga Seu Steleophaga 50-130 weight portion
Folium Artemisiae Argyi 140-200 weight portion Rhizoma Corydalis (processed with vinegar) 50-130 weight portion
Pericarpium Zanthoxyli 120-240 weight portion Sanguis Draxonis 30-90 weight portion
Olibanum 20-40 weight portion Herba Lycopodii 100-200 weight portion
Active careless 120-240 weight portion Lignum Sappan 120-240 weight portion
Mentholum 100-180 weight portion Camphora 80-160 weight portion
Borneolum Syntheticum 100-160 weight portion.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Herba Veronicae Peregrinae 148 weight portion Radix Angelicae Sinensis 90 weight portions
Cortex Acanthopancis 179 weight portion Radix Angelicae Pubescentiss 118 weight portions
Rhizoma Et Radix Notopterygii 118 weight portion vinegar system rhizoma sparganic 71 weight portions
Rhizoma Curcumae (processed with vinegar) 71 weight portion Eupolyphaga Seu Steleophagas 90 weight portions
Folium Artemisiae Argyi 171 weight portion Rhizoma Corydalis (processed with vinegar) 90 weight portions
Pericarpium Zanthoxyli 179 weight portion Sanguis Draxonis 60 weight portions
Olibanum 30 weight portion Herba Lycopodiis 148 weight portions
Active careless 179 weight portion Lignum Sappans, 179 weight portions
Mentholum 142 weight portion Camphoras 120 weight portions
Borneolum Syntheticum 130 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Herba Veronicae Peregrinae 190 weight portion Radix Angelicae Sinensis 60 weight portions
Cortex Acanthopancis 130 weight portion Radix Angelicae Pubescentiss 150 weight portions
Rhizoma Et Radix Notopterygii 150 weight portion vinegar system rhizoma sparganic 50 weight portions
Rhizoma Curcumae (processed with vinegar) 50 weight portion Eupolyphaga Seu Steleophagas 120 weight portions
Folium Artemisiae Argyi 190 weight portion Rhizoma Corydalis (processed with vinegar) 60 weight portions
Pericarpium Zanthoxyli 130 weight portion Sanguis Draxonis 85 weight portions
Olibanum 35 weight portion Herba Lycopodiis 110 weight portions
Active careless 130 weight portion Lignum Sappans, 230 weight portions
Mentholum 170 weight portion Camphoras 90 weight portions
Borneolum Syntheticum 110 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Herba Veronicae Peregrinae 110 weight portion Radix Angelicae Sinensis 120 weight portions
Cortex Acanthopancis 230 weight portion Radix Angelicae Pubescentiss 80 weight portions
Rhizoma Et Radix Notopterygii 80 weight portion vinegar system rhizoma sparganic 90 weight portions
Rhizoma Curcumae (processed with vinegar) 90 weight portion Eupolyphaga Seu Steleophagas 60 weight portions
Folium Artemisiae Argyi 150 weight portion Rhizoma Corydalis (processed with vinegar) 120 weight portions
Pericarpium Zanthoxyli 230 weight portion Sanguis Draxonis 35 weight portions
Olibanum 25 weight portion Herba Lycopodiis 190 weight portions
Active careless 230 weight portion Lignum Sappans, 130 weight portions
Mentholum 110 weight portion Camphoras 150 weight portions
Borneolum Syntheticum 150 weight portions.
Pharmaceutical composition of the present invention adds conventional adjuvant, according to common process, make tablet, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid or ejection preparation.
Preparation of drug combination method of the present invention can also comprise:
Getting Herba Veronicae Peregrinae, vinegar system rhizoma sparganic, Rhizoma Curcumae (processed with vinegar), Eupolyphaga Seu Steleophaga, Rhizoma Corydalis (processed with vinegar), active grass decocts with water 1-3 time, each 1-3 hour, collecting decoction, filter, recording filtrate simmer down to relative density under 80-100 ℃ is the clear paste of 1.05-1.20, the ethanol that adds 1-3 times of weight portion left standstill 12-36 hour, got supernatant; In addition Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Cortex Acanthopancis, Folium Artemisiae Argyi, Pericarpium Zanthoxyli, Lignum Sappan, Herba Lycopodii are ground into coarse powder, Sanguis Draxonis is ground into coarse powder, mixes, with 60-70% soak with ethanol after 90-100 hour forced circulation 3-6 hour, filter, collect filtrate, mix with supernatant, left standstill 12-36 hour, filter; In addition with Mentholum, Camphora, Borneolum Syntheticum dissolve with ethanol, in adding medicinal liquid behind the 9-15 parts by volume Moschus type essence mix homogeneously, with 100-300 parts by volume glycerol mixing, add conventional adjuvant according to a conventional method and make tablet, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid or ejection preparation again.
Preparation of drug combination method of the present invention is preferably:
Getting Herba Veronicae Peregrinae, vinegar system rhizoma sparganic, Rhizoma Curcumae (processed with vinegar), Eupolyphaga Seu Steleophaga, Rhizoma Corydalis (processed with vinegar), active grass decocts with water 2 times, each 2 hours, collecting decoction, filter, recording filtrate simmer down to relative density under 90 ℃ is the clear paste of 1.11-1.15, the ethanol that adds 2 times of weight portions left standstill 24 hours, got supernatant; In addition with Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Cortex Acanthopancis, Folium Artemisiae Argyi, Pericarpium Zanthoxyli, Lignum Sappan, Herba Lycopodii is ground into coarse powder, Sanguis Draxonis is ground into coarse powder, mix, with 65% soak with ethanol forced circulation 4.5 hours after 96 hours, filter, collect filtrate, mix with supernatant, left standstill 24 hours, filter, in addition with Mentholum, Camphora, the Borneolum Syntheticum dissolve with ethanol, in adding medicinal liquid behind the 12 parts by volume Moschus type essence mix homogeneously, with 200 parts by volume glycerol mixings, add conventional adjuvant according to a conventional method and make tablet again, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, the soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid or ejection preparation.
The discrimination method of the Borneolum Syntheticum in the pharmaceutical composition of the present invention comprises the steps:
Accurate absorption pharmaceutical composition 1-3 parts by volume of the present invention is put in the 10 parts by volume measuring bottles, adds ethanol dilution to scale, shakes up, as need testing solution; Get the Borneolum Syntheticum reference substance, add dissolve with ethanol, make the solution that every 0.1-2 parts by volume contains the 4-6 parts by volume, in contrast product solution; According to thin layer chromatography (57 pages of appendix) test, draw above-mentioned each 0.0005-0.0015 parts by volume of two kinds of solution, put respectively on same silica gel g thin-layer plate, with the ethyl acetate is developing solvent, launches, and takes out, dry, spray is with the 5-15% phosphomolybdic acid ethanol solution, 85-125 ℃ of baking 5-10 minute; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
The discrimination method of the Borneolum Syntheticum in the pharmaceutical composition of the present invention comprises the steps:
Accurate this product pharmaceutical composition 2 parts by volume of the present invention of drawing are put in the 10 parts by volume measuring bottles, add ethanol dilution to scale, shake up, as need testing solution; Get the Borneolum Syntheticum reference substance, add dissolve with ethanol, make the solution that per 1 parts by volume contains 5 parts by volume, in contrast product solution; According to thin layer chromatography (57 pages of appendix) test, draw each 0.001 parts by volume of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with the ethyl acetate is developing solvent, launches, and takes out, dry, spray is with 10% phosphomolybdic acid ethanol solution, 105 ℃ of bakings 5-10 minute.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Check: amount of alcohol should be 51-59%, and loading amount, microbial limit should meet every regulation relevant under the Chinese Pharmacopoeia tincture item.
Wherein, described weight portion and parts by volume are the relations of g/ml.
Pharmaceutical composition of the present invention has blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, the effect of expelling wind and cold.Be used for the treatment of traumatic injury, long-pending swelling due to stasis, the waist numbness, the rheumatic ostalgia effect is remarkable.
Experiment and embodiment are used to further specify but are not limited to the present invention below.
Experimental example 1 to experimental example 5 all adopts following test material:
Experiment purpose: the analgesia of pharmaceutical composition of the present invention and blood stasis dispelling effect
Test drug: pharmaceutical composition medicinal liquid of the present invention is provided by Zhongzhou Pianziguang Pharmaceutical Industry Co., Ltd..
Experimental animal: cleaning level ICR mice and SD rat, Shanghai Slac Experimental Animal Co., Ltd.'s supply, credit number SCSK (Shanghai) 2003-0003.
Experimental example 1: pharmaceutical composition medicinal liquid of the present invention is to the analgesic activity of mouse writhing method pain model
Grouping: 60 of mices, body weight 18-20g, male.Be divided into 6 groups at random by body weight: model control group (50% ethanol), diclofenac group (1% diclofenac sodium, Novartis Pharma AG, lot number X0175), pharmaceutical composition stock solution group of the present invention, with the 50% concentration pharmaceutical composition liquid dose of the present invention group of 50% ethanol dilution, 10 every group.
Method: skin coating every day 1 time after the mouse web portion cropping, continuous 2 days, 10min after the last administration, lumbar injection 0.6% acetic acid 10ml/kg, and in after this 10min, 20min, 30min the writhing response number of times of record mice, calculate pain suppression ratio %=(control group mice is turned round body number-administration group mouse writhing number)/control group mice and turn round body number * 100%
Statistical analysis: experimental data with
Figure G2009100775381D0000051
Expression, group difference adopts one factor analysis of variance.The results are shown in Table 1
Table 1 pharmaceutical composition medicinal liquid of the present invention is to the analgesic activity of mouse writhing method pain model
Figure G2009100775381D0000052
Compare with simple model group, *: p<0.05, * *: P<0.01. and pharmaceutical composition stock solution group of the present invention compare, and #:p<0.05.##:p<0.01. and 50% pharmaceutical composition medicinal liquid group of the present invention compare △: P<0.05, △ △: P<0.01.
Experimental example 2: pharmaceutical composition of the present invention is to the contract analgesia method of tail method pain model of mice hot water
Method: 60 of mices, body weight 18-20g, male.Mouse tail is placed 48.0 ℃ of waters bath with thermostatic control, immersion length is 3cm, with the afterbody retraction is the pain reaction sign, the record mice is put into water-bath to the time that begins to bounce back from afterbody, and by this time mice is divided into 6 groups at random, i.e. model control group (50% ethanol), diclofenac (1% diclofenac sodium) group, pharmaceutical composition stock solution group of the present invention, with the 50% concentration pharmaceutical composition liquid dose of the present invention group of 50% ethanol dilution, 10 every group.After the mice group, tail skin coating every day 1 time, continuous 2 days, 10min, 40min, 70min after the last administration surveyed mice again and put into water-bath from afterbody and begin time of beginning to bounce back to tail.
Statistical analysis: experimental data with
Figure G2009100775381D0000053
Expression, group difference adopts one factor analysis of variance.The results are shown in Table 2.
Table 2 pharmaceutical composition medicinal liquid of the present invention is to the contract analgesic activity of tail method pain model of mice hot water
Figure G2009100775381D0000061
Compare with model control group, *: p<0.05, * *: p<0.01. and C medicine stock solution group compare, and #:p<0.05.##:p<0.01. and 50%C medicinal liquid group compare, △: p<0.05, △ △: p<0.01.
Experimental example 3: pharmaceutical composition medicinal liquid of the present invention is to the antiinflammatory action of mice ear method inflammatory model
Grouping: 60 of mices, body weight 18-20g, male, be divided into 6 groups at random by body weight: model control group (50% ethanol), diclofenac (1% diclofenac sodium) group, pharmaceutical composition stock solution group of the present invention, with the 50% concentration pharmaceutical composition liquid dose of the present invention group of 50% ethanol dilution, 10 every group.
Method: two surface skin coating every days 1 time before and after the mouse right ear shell, continuous 2 days, 10min after the last administration got dimethylbenzene 0.02mL with injector and is applied to two sides before and after the auris dextra shell equably, and left ear compares.Cause scorching back 0.5h repaste and be subjected to reagent.Extremely scorching back 3h takes off cervical vertebra with mice and puts to death, and cuts ears along the auricular concha base portion, locates to sweep away auricle in the ears symmetry with the rustless steel card punch of diameter 8mm, weighs on electronic analytical balance.And calculate its swelling rate %=(auris dextra sheet weight-left auricle weight)/left auricle weight * 100%
Statistical analysis: experimental data
Figure G2009100775381D0000062
Expression, group difference adopts one factor analysis of variance.The results are shown in Table 3.
Table 3 pharmaceutical composition medicinal liquid of the present invention is to the antiinflammatory action of mice ear method inflammatory model
Figure G2009100775381D0000063
Compare with simple model group, *: p<0.05, * *: p<0.01. and C medicine stock solution group compare, #:p<0.05, ##:p<0.01. and 50%C medicinal liquid group compare, △: p<0.05, △ △: p<0.01
Experimental example 4: pharmaceutical composition medicinal liquid of the present invention is to the antiinflammatory action of mice foot pawl swelling method inflammatory model
Grouping: 60 of mices, body weight 18-20g, male.Be divided into 6 groups at random by body weight: model control group (50% ethanol), diclofenac 1% diclofenac sodium) group, pharmaceutical composition stock solution group of the present invention, with the 50% concentration pharmaceutical composition liquid dose of the present invention group of 50% ethanol dilution, 10 every group.
Method: the right skin of foot coating of mice every day 1 time, continuous 2 days, 10min after the last administration, in right back sufficient plantar subcutaneous injection 1.0% carrageenin solution 0.03ml, right foot compares.Cause scorching back 4h mice is taken off cervical vertebra execution, cut biped, on electronic analytical balance, weigh along ankle joint.Calculate its swelling rate %=(right heavy sensation in the foot amount-left heavy sensation in the foot amount)/left heavy sensation in the foot amount * 100%
Statistical analysis: experimental data
Figure G2009100775381D0000071
Expression, group difference adopts one factor analysis of variance.The results are shown in Table 4.
Table 4 pharmaceutical composition medicinal liquid of the present invention is to the antiinflammatory action of mice foot pawl swelling method inflammatory model
Compare with simple model group, *: p<0.05, * *: p<0.01. and pharmaceutical composition stock solution group of the present invention compare, #:P<0.05, ##:p<0.01. and 50% pharmaceutical composition medicinal liquid group of the present invention compare △: p<0.05, △ △: p<0.01
Experimental example 5: pharmaceutical composition medicinal liquid of the present invention is to the blood stasis dispelling effect of the traumatic ecchymosis of rat local skin
Method: 60 of rats, body weight 180-200g, male and female half and half.Rat back is with 10%Na2S about 5 * 4cm2 that loses hair or feathers.With vice bark pocket skin, firmly increase gradually behind the 24h,, occur ecchymosis behind the 1h, observe the rat impingement edema ecchymosis situation of respectively organizing, and calculate the ecchymosis area, draw every Mus integration according to table 5 to cause subcutaneous hemorrhage degree of being.Be divided into 6 groups at random by integration: model control group (50% ethanol), diclofenac (1% diclofenac sodium) group, pharmaceutical composition stock solution group of the present invention, with the 50% concentration pharmaceutical composition liquid dose of the present invention group of 50% ethanol dilution, respectively 5 of every group of male and female.Smear the ecchymosis place with medicine respectively immediately, every day 2 times, coating and observation are 4 days continuously.See Table 5.
The standards of grading of the traumatic ecchymosis of table 5
Figure G2009100775381D0000081
Statistical analysis: experimental data with
Figure G2009100775381D0000082
Expression, group difference adopts one factor analysis of variance.The results are shown in Table 6.
Table 6 pharmaceutical composition medicinal liquid of the present invention turns into the blood stasis dispelling of the traumatic ecchymosis of rat local skin
Figure G2009100775381D0000083
Compare with simple model group, *: p<0.05, * *: P<0.01. and pharmaceutical composition stock solution group of the present invention are relatively.#:p<0.05,##:p<0.01。Compare △: p<0.05, △ △: p<0.01 with 50% pharmaceutical composition medicinal liquid group of the present invention
More than five tests show, pharmaceutical composition of the present invention when the coating administration of part, muroid all had more significantly ease pain, detumescence, antiinflammatory and blood stasis dispelling effect.
Experimental example 6 to experimental example 7 all adopts following test material:
Test objective: observe mice local skin administration and gavage the acute toxic reaction that occurs behind the pharmaceutical composition medicinal liquid of the present invention.
Test drug: pharmaceutical composition medicinal liquid of the present invention is provided by Zhongzhou Pianziguang Pharmaceutical Industry Co., Ltd..
Experimental animal: cleaning level ICR mice, Shanghai Slac Experimental Animal Co., Ltd.'s supply, credit number SCXK (Shanghai) 2003-0003.
Experimental example 6: pharmaceutical composition medicinal liquid local skin administration acute toxicity testing of the present invention
Can't measure in evidence on its plinth of median lethal dose(LD 50) (LD50) of mice local skin administration pharmaceutical composition medicinal liquid of the present invention, get 20 of Mus, each half of male and female, body weight 18-20g, with pharmaceutical composition medicinal liquid stock solution of the present invention, 3 times on the one abdominal skins (2 * 3cm2) administrations, and observed and recorded is tried local skin and the survival condition of Mus continuously.
As a result, the continuous observation 7 after the administration, all are tried, and the Mus local skin does not all have redness or other are obviously unusual, and all survivals in the observation period are taken off neck execution and are observed each main organs, show no obvious abnormalities.Above-mentioned test points out two medicines all not have the local toxicity effect.
Experimental example 7: pharmaceutical composition medicinal liquid gastric infusion acute toxicity testing of the present invention
After mouse stomach (ig) pharmaceutical composition 0% of the present invention and 100% estimation lethal dose are found out in test at the beginning of giving, with middle dosage and basis, adopt to go up earlier and then descend the geometric ratio dosed administration, continuous observed and recorded is tried behavior state and the survival condition behind the Mus ig pharmaceutical composition medicinal liquid of the present invention.
As a result, 2-10min excitement all occurs, goes up jumping, rapid breathing, prostrate motionless behind the mice ig pharmaceutical composition medicinal liquid of the present invention, is the drunk shape of the degree of depth, recovers gradually or death behind the 1-3h.The median lethal dose(LD 50) (LD50) of mice ig pharmaceutical composition medicinal liquid of the present invention is 18.69ml/kg, the 95% credible 17.74-19.69ml/kg (table 7) that is limited to of LD50
The chmice acute toxicity test of table 7 pharmaceutical composition medicinal liquid of the present invention (ig)
95% fiducial limit of L95:LD50.
Conclusion: during pharmaceutical composition local skin administration of the present invention, mice is not all had tangible acute toxicity.The LD50 of mice ig pharmaceutical composition medicinal liquid of the present invention is 18.69ml/kg (the 95% credible 17.74-19.69ml/kg that is limited to of LD50).
Following embodiment all can realize the effect of above-mentioned experimental example.
Embodiment 1: the preparation of capsule
Herba Veronicae Peregrinae 148g Radix Angelicae Sinensis 90g
Cortex Acanthopancis 179g Radix Angelicae Pubescentis 118g
Rhizoma Et Radix Notopterygii 118g vinegar system rhizoma sparganic 71g
Rhizoma Curcumae (processed with vinegar) 71g Eupolyphaga Seu Steleophaga 90g
Folium Artemisiae Argyi 171g Rhizoma Corydalis (processed with vinegar) 90g
Pericarpium Zanthoxyli 179g Sanguis Draxonis 60g
Olibanum 30g Herba Lycopodii 148g
Active careless 179g Lignum Sappan 179g
Mentholum 142g Camphora 120g
Borneolum Syntheticum 130g;
Get Herba Veronicae Peregrinae, vinegar system rhizoma sparganic, Rhizoma Curcumae (processed with vinegar), Eupolyphaga Seu Steleophaga, Rhizoma Corydalis (processed with vinegar), active grass and decoct with water 2 times, each 2 hours, collecting decoction, filter, recording filtrate simmer down to relative density under 90 ℃ is the clear paste of 1.11-1.15, adds 2 times of amount ethanol, left standstill 24 hours, and got supernatant; In addition Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Cortex Acanthopancis, Folium Artemisiae Argyi, Pericarpium Zanthoxyli, Lignum Sappan, Herba Lycopodii are ground into coarse powder, Sanguis Draxonis is ground into coarse powder, mixes, with 65% soak with ethanol forced circulation 4.5 hours after 96 hours, filter, collect filtrate, mix with supernatant, left standstill 24 hours, filter, in addition with Mentholum, Camphora, Borneolum Syntheticum dissolve with ethanol, in adding medicinal liquid behind the 12ml Moschus type essence mix homogeneously, with 200ml glycerol mixing, make capsule again according to conventional method.
Embodiment 2: the preparation of powder
Herba Veronicae Peregrinae 190g Radix Angelicae Sinensis 60g
Cortex Acanthopancis 130g Radix Angelicae Pubescentis 150g
Rhizoma Et Radix Notopterygii 150g vinegar system rhizoma sparganic 50g
Rhizoma Curcumae (processed with vinegar) 50g Eupolyphaga Seu Steleophaga 120g
Folium Artemisiae Argyi 190g Rhizoma Corydalis (processed with vinegar) 60g
Pericarpium Zanthoxyli 130g Sanguis Draxonis 85g
Olibanum 35g Herba Lycopodii 110g
Active careless 130g Lignum Sappan 230g
Mentholum 170g Camphora 90g
Borneolum Syntheticum 110g;
Get Herba Veronicae Peregrinae, vinegar system rhizoma sparganic, Rhizoma Curcumae (processed with vinegar), Eupolyphaga Seu Steleophaga, Rhizoma Corydalis (processed with vinegar), active grass and decoct with water 2 times, each 2 hours, collecting decoction, filter, recording filtrate simmer down to relative density under 90 ℃ is the clear paste of 1.11-1.15, adds 2 times of amount ethanol, left standstill 24 hours, and got supernatant; In addition Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Cortex Acanthopancis, Folium Artemisiae Argyi, Pericarpium Zanthoxyli, Lignum Sappan, Herba Lycopodii are ground into coarse powder, Sanguis Draxonis is ground into coarse powder, mixes, with 65% soak with ethanol forced circulation 4.5 hours after 96 hours, filter, collect filtrate, mix with supernatant, left standstill 24 hours, filter, in addition with Mentholum, Camphora, Borneolum Syntheticum dissolve with ethanol, in adding medicinal liquid behind the 12ml Moschus type essence mix homogeneously, with 200ml glycerol mixing, make random notes again according to conventional method.
Embodiment 3: the preparation of ointment
Herba Veronicae Peregrinae 110g Radix Angelicae Sinensis 120g
Cortex Acanthopancis 230g Radix Angelicae Pubescentis 80g
Rhizoma Et Radix Notopterygii 80g vinegar system rhizoma sparganic 90g
Rhizoma Curcumae (processed with vinegar) 90g Eupolyphaga Seu Steleophaga 60g
Folium Artemisiae Argyi 150g Rhizoma Corydalis (processed with vinegar) 120g
Pericarpium Zanthoxyli 230g Sanguis Draxonis 35g
Olibanum 25g Herba Lycopodii 190g
Active careless 230g Lignum Sappan 130g
Mentholum 110g Camphora 150g
Borneolum Syntheticum 150g;
Get Herba Veronicae Peregrinae, vinegar system rhizoma sparganic, Rhizoma Curcumae (processed with vinegar), Eupolyphaga Seu Steleophaga, Rhizoma Corydalis (processed with vinegar), active grass and decoct with water 2 times, each 2 hours, collecting decoction, filter, recording filtrate simmer down to relative density under 90 ℃ is the clear paste of 1.11-1.15, adds 2 times of amount ethanol, left standstill 24 hours, and got supernatant; In addition Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Cortex Acanthopancis, Folium Artemisiae Argyi, Pericarpium Zanthoxyli, Lignum Sappan, Herba Lycopodii are ground into coarse powder, Sanguis Draxonis is ground into coarse powder, mixes, with 65% soak with ethanol forced circulation 4.5 hours after 96 hours, filter, collect filtrate, mix with supernatant, left standstill 24 hours, filter, in addition with Mentholum, Camphora, Borneolum Syntheticum dissolve with ethanol, in adding medicinal liquid behind the 12ml Moschus type essence mix homogeneously, with 200ml glycerol mixing, make ointment again according to conventional method.
Embodiment 4: the discrimination method of the Borneolum Syntheticum in the pharmaceutical composition of the present invention
Accurate this product 2ml that draws puts in the 10ml measuring bottle, adds ethanol dilution to scale, shakes up, as need testing solution; Get the Borneolum Syntheticum reference substance, add dissolve with ethanol, make the solution that every 1ml contains 5ml, in contrast product solution; According to thin layer chromatography (57 pages of appendix) test, draw each 1 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developing solvent with the ethyl acetate, launch, take out, to dry, spray is with 10% phosphomolybdic acid ethanol solution, 105 ℃ of bakings 5-10 minute.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Embodiment 5: the discrimination method of the Borneolum Syntheticum in the pharmaceutical composition of the present invention
Accurate this product 1.5ml that draws puts in the 10ml measuring bottle, adds ethanol dilution to scale, shakes up, as need testing solution; Get the Borneolum Syntheticum reference substance, add dissolve with ethanol, make the solution that every 1.8ml contains 4.5ml, in contrast product solution; According to thin layer chromatography (57 pages of appendix) test, draw each 0.55 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developing solvent with the ethyl acetate, launch, take out, to dry, spray is with 8% phosphomolybdic acid ethanol solution, 120 ℃ of bakings 5-10 minute.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Embodiment 6: the discrimination method of the Borneolum Syntheticum in the pharmaceutical composition of the present invention
Accurate this product 2.5ml that draws puts in the 10ml measuring bottle, adds ethanol dilution to scale, shakes up, as need testing solution; Get the Borneolum Syntheticum reference substance, add dissolve with ethanol, make the solution that every 0.5ml contains 5.5ml, in contrast product solution; According to thin layer chromatography (57 pages of appendix) test, draw each 1.3 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, be developing solvent with the ethyl acetate, launch, take out, to dry, spray is with 12% phosphomolybdic acid ethanol solution, 90 ℃ of bakings 5-10 minute.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.

Claims (10)

1. pharmaceutical composition for the treatment of traumatic injury, rheumatic ostalgia is characterized in that the crude drug of this pharmaceutical composition consists of:
Herba Veronicae Peregrinae 100-200 weight portion Radix Angelicae Sinensis 50-130 weight portion
Cortex Acanthopancis 120-240 weight portion Radix Angelicae Pubescentis 70-160 weight portion
Rhizoma Et Radix Notopterygii 70-160 weight portion vinegar system rhizoma sparganic 40-100 weight portion
Rhizoma Curcumae (processed with vinegar) 40-100 weight portion Eupolyphaga Seu Steleophaga 50-130 weight portion
Folium Artemisiae Argyi 140-200 weight portion Rhizoma Corydalis (processed with vinegar) 50-130 weight portion
Pericarpium Zanthoxyli 120-240 weight portion Sanguis Draxonis 30-90 weight portion
Olibanum 20-40 weight portion Herba Lycopodii 100-200 weight portion
Active careless 120-240 weight portion Lignum Sappan 120-240 weight portion
Mentholum 100-180 weight portion Camphora 80-160 weight portion
Borneolum Syntheticum 100-160 weight portion.
2. pharmaceutical composition as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Herba Veronicae Peregrinae 148 weight portion Radix Angelicae Sinensis 90 weight portions
Cortex Acanthopancis 179 weight portion Radix Angelicae Pubescentiss 118 weight portions
Rhizoma Et Radix Notopterygii 118 weight portion vinegar system rhizoma sparganic 71 weight portions
Rhizoma Curcumae (processed with vinegar) 71 weight portion Eupolyphaga Seu Steleophagas 90 weight portions
Folium Artemisiae Argyi 171 weight portion Rhizoma Corydalis (processed with vinegar) 90 weight portions
Pericarpium Zanthoxyli 179 weight portion Sanguis Draxonis 60 weight portions
Olibanum 30 weight portion Herba Lycopodiis 148 weight portions
Active careless 179 weight portion Lignum Sappans, 179 weight portions
Mentholum 142 weight portion Camphoras 120 weight portions
Borneolum Syntheticum 130 weight portions.
3. pharmaceutical composition as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Herba Veronicae Peregrinae 190 weight portion Radix Angelicae Sinensis 60 weight portions
Cortex Acanthopancis 130 weight portion Radix Angelicae Pubescentiss 150 weight portions
Rhizoma Et Radix Notopterygii 150 weight portion vinegar system rhizoma sparganic 50 weight portions
Rhizoma Curcumae (processed with vinegar) 50 weight portion Eupolyphaga Seu Steleophagas 120 weight portions
Folium Artemisiae Argyi 190 weight portion Rhizoma Corydalis (processed with vinegar) 60 weight portions
Pericarpium Zanthoxyli 130 weight portion Sanguis Draxonis 85 weight portions
Olibanum 35 weight portion Herba Lycopodiis 110 weight portions
Active careless 130 weight portion Lignum Sappans, 230 weight portions
Mentholum 170 weight portion Camphoras 90 weight portions
Borneolum Syntheticum 110 weight portions.
4. pharmaceutical composition as claimed in claim 1 is characterized in that the crude drug of this pharmaceutical composition consists of:
Herba Veronicae Peregrinae 110 weight portion Radix Angelicae Sinensis 120 weight portions
Cortex Acanthopancis 230 weight portion Radix Angelicae Pubescentiss 80 weight portions
Rhizoma Et Radix Notopterygii 80 weight portion vinegar system rhizoma sparganic 90 weight portions
Rhizoma Curcumae (processed with vinegar) 90 weight portion Eupolyphaga Seu Steleophagas 60 weight portions
Folium Artemisiae Argyi 150 weight portion Rhizoma Corydalis (processed with vinegar) 120 weight portions
Pericarpium Zanthoxyli 230 weight portion Sanguis Draxonis 35 weight portions
Olibanum 25 weight portion Herba Lycopodiis 190 weight portions
Active careless 230 weight portion Lignum Sappans, 130 weight portions
Mentholum 110 weight portion Camphoras 150 weight portions
Borneolum Syntheticum 150 weight portions.
5. as the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that said composition adds conventional adjuvant, according to common process, make tablet, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid or ejection preparation.
6. as the arbitrary described preparation of drug combination method of claim 1-4, it is characterized in that this method is:
Getting Herba Veronicae Peregrinae, vinegar system rhizoma sparganic, Rhizoma Curcumae (processed with vinegar), Eupolyphaga Seu Steleophaga, Rhizoma Corydalis (processed with vinegar), active grass decocts with water 1-3 time, each 1-3 hour, collecting decoction, filter, recording filtrate simmer down to relative density under 80-100 ℃ is the clear paste of 1.05-1.20, the ethanol that adds 1-3 times of weight portion left standstill 12-36 hour, got supernatant; In addition Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Cortex Acanthopancis, Folium Artemisiae Argyi, Pericarpium Zanthoxyli, Lignum Sappan, Herba Lycopodii are ground into coarse powder, Sanguis Draxonis is ground into coarse powder, mixes, with 60-70% soak with ethanol after 90-100 hour forced circulation 3-6 hour, filter, collect filtrate, mix with supernatant, left standstill 12-36 hour, filter; In addition with Mentholum, Camphora, Borneolum Syntheticum dissolve with ethanol, in adding medicinal liquid behind the 9-15 parts by volume Moschus type essence mix homogeneously, with 100-300 parts by volume glycerol mixing, add conventional adjuvant according to a conventional method and make tablet, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid or ejection preparation again.
7. preparation of drug combination method as claimed in claim 6 is characterized in that this method is:
Getting Herba Veronicae Peregrinae, vinegar system rhizoma sparganic, Rhizoma Curcumae (processed with vinegar), Eupolyphaga Seu Steleophaga, Rhizoma Corydalis (processed with vinegar), active grass decocts with water 2 times, each 2 hours, collecting decoction, filter, recording filtrate simmer down to relative density under 90 ℃ is the clear paste of 1.11-1.15, the ethanol that adds 2 times of weight portions left standstill 24 hours, got supernatant; In addition with Radix Angelicae Sinensis, Rhizoma Et Radix Notopterygii, Radix Angelicae Pubescentis, Cortex Acanthopancis, Folium Artemisiae Argyi, Pericarpium Zanthoxyli, Lignum Sappan, Herba Lycopodii is ground into coarse powder, Sanguis Draxonis is ground into coarse powder, mix, with 65% soak with ethanol forced circulation 4.5 hours after 96 hours, filter, collect filtrate, mix with supernatant, left standstill 24 hours, filter, in addition with Mentholum, Camphora, the Borneolum Syntheticum dissolve with ethanol, in adding medicinal liquid behind the 12 parts by volume Moschus type essence mix homogeneously, with 200 parts by volume glycerol mixings, add conventional adjuvant according to a conventional method and make tablet again, capsule, powder, soft capsule, drop pill, honeyed pill, pill, granule, the soft extract with bee honey agent, slow releasing preparation, quick releasing formulation, controlled release preparation, oral liquid or ejection preparation.
8. as the discrimination method of the arbitrary described pharmaceutical composition of claim 1-4, it is characterized in that the discrimination method of Borneolum Syntheticum in this pharmaceutical composition comprises the steps:
Accurate absorption pharmaceutical composition 1-3 parts by volume of the present invention is put in the 10 parts by volume measuring bottles, adds ethanol dilution to scale, shakes up, as need testing solution; Get the Borneolum Syntheticum reference substance, add dissolve with ethanol, make the solution that every 0.1-2 parts by volume contains the 4-6 parts by volume, in contrast product solution; Test according to thin layer chromatography, drawing above-mentioned each 0.0005-0.0015 parts by volume of two kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with the ethyl acetate, launch, take out, dry, spray is with the 5-15% phosphomolybdic acid ethanol solution, 85-125 ℃ of baking 5-10 minute, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color; Amount of alcohol is 51-59% during inspection, and loading amount, microbial limit meet every regulation relevant under the Chinese Pharmacopoeia tincture item.
9. the discrimination method of pharmaceutical composition as claimed in claim 8 is characterized in that the discrimination method of Borneolum Syntheticum in this pharmaceutical composition comprises the steps:
Accurate absorption pharmaceutical composition 2 parts by volume of the present invention are put in the 10 parts by volume measuring bottles, add ethanol dilution to scale, shake up, as need testing solution; Get the Borneolum Syntheticum reference substance, add dissolve with ethanol, make the solution that per 1 parts by volume contains 5 parts by volume, in contrast product solution; Test according to thin layer chromatography, drawing each 0.001 parts by volume of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, is developing solvent with the ethyl acetate, launch, take out, dry, spray is with 10% phosphomolybdic acid ethanol solution, 105 ℃ of bakings 5-10 minute, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color; Amount of alcohol is 51-59% during inspection, and loading amount, microbial limit meet every regulation relevant under the Chinese Pharmacopoeia tincture item.
10. as the application of the arbitrary described pharmaceutical composition of claim 1-4 in preparation treatment traumatic injury or rheumatic ostalgia medicine.
CN200910077538A 2009-01-22 2009-01-22 Medicine combination for traumatic injury and rheumatoid arthritis treatment Pending CN101785840A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200910077538A CN101785840A (en) 2009-01-22 2009-01-22 Medicine combination for traumatic injury and rheumatoid arthritis treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200910077538A CN101785840A (en) 2009-01-22 2009-01-22 Medicine combination for traumatic injury and rheumatoid arthritis treatment

Publications (1)

Publication Number Publication Date
CN101785840A true CN101785840A (en) 2010-07-28

Family

ID=42529312

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200910077538A Pending CN101785840A (en) 2009-01-22 2009-01-22 Medicine combination for traumatic injury and rheumatoid arthritis treatment

Country Status (1)

Country Link
CN (1) CN101785840A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961633A (en) * 2012-11-19 2013-03-13 贵州苗珍堂生物科技有限公司 Preparation for treating postpartum rheumatism
CN110075245A (en) * 2019-05-17 2019-08-02 王春 A kind of Chinese medicine composition and preparation method thereof with no addiction analgesic efficacy

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102961633A (en) * 2012-11-19 2013-03-13 贵州苗珍堂生物科技有限公司 Preparation for treating postpartum rheumatism
CN102961633B (en) * 2012-11-19 2017-11-03 贵州苗珍堂生物科技有限公司 A kind of preparation for being used to treat postpartum rheumatism
CN110075245A (en) * 2019-05-17 2019-08-02 王春 A kind of Chinese medicine composition and preparation method thereof with no addiction analgesic efficacy

Similar Documents

Publication Publication Date Title
JP6039421B2 (en) Method for producing herbal medicine composition for anti-inflammatory / anti-tumor / pain relief and its application
CN109431965A (en) Pharmaceutical formulation and its use
CN103381217B (en) A kind of Liuweibuxue capsule and method of quality control thereof and application
CN103961636B (en) Orthopedic disease treatment external application traditional Chinese medicine composition, preparation method and application thereof
CN101239168A (en) Composition with ease pain anti-inflammatory action
CN102068474A (en) Capparis spinosa fruit gel ointment, production method thereof, and application thereof to antirheumatic medicaments
CN104274546B (en) A kind of external medicine composition, traditional Chinese medicine for outer use and its preparation method and application
Panday et al. Effect of root-extracts of Ficus benghalensis (Banyan) in pain in animal models
CN105434511B (en) A kind of hymsleya amabilis medicine materical crude slice and its preparation method and application
CN101785840A (en) Medicine combination for traumatic injury and rheumatoid arthritis treatment
CN101317959B (en) Mastitis plaster for animals preparation and feeding method thereof
CN102302615B (en) Effective site group of daphne giraldii nitsche leaf, preparation method, medicinal composition and application thereof
CN102309689B (en) Gastrodia elata chewing gum agent, preparation method and detection method thereof
CN107693532A (en) Compound anti-parasitic preparation and preparation method thereof
CN106535912B (en) Control pharmaceutical composition and its application of human body blood fat and body weight
CN104173922B (en) A kind of Chinese medicine for treating goiter
CN102940684B (en) A kind of Chinese medicine composition containing Radix Illicii Lanceolati and preparation method thereof
CN103432217B (en) External medicine composition for treating rheumatoid arthritis, preparation method and application of external medicine composition
CN102940685A (en) Lanceleaf anisetree extract and external transdermal absorption agent containing lanceleaf anisetree extract
Khatak et al. A comparative study: Homoeopathic medicine and arnmedicinal plant Withania somnifera for antidiabeticrnactivity
CN101214328A (en) Medicament for treating rheumatism wind-dampness pain and preparation thereof
CN104436022A (en) Hemsleya-macrosperma-containing traditional Chinese medicine composition for treating diabetes mellitus
CN1935223A (en) Chinese medicine composition, and its preparing method and quality control method
CN109528917A (en) A kind of preparation method towards hospital's composition and its cream for treating rheumatoid arthritis
CN102631395A (en) Rape pollen dispersible tablet for treating prostatitis and preparation method of rape pollen dispersible tablet

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100728